{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:14:38Z","timestamp":1760908478601},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1157\/13111687","type":"journal-article","created":{"date-parts":[[2009,1,6]],"date-time":"2009-01-06T17:29:07Z","timestamp":1231262947000},"page":"525-529","source":"Crossref","is-referenced-by-count":7,"title":["Hepatitis t\u00f3xica por imatinib: descripci\u00f3n de dos casos y revisi\u00f3n de la literatura m\u00e9dica"],"prefix":"10.1016","volume":"30","author":[{"given":"Francisco","family":"Fuster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolando","family":"Vallansot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miquel","family":"Granell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miquel","family":"Bruguera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13111687_bib1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate: a new oral targeted therapy","volume":"346","author":"Savage","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1157\/13111687_bib2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1634\/theoncologist.9-3-271","article-title":"Indications for imatinib mesylate therapy and clinical management","volume":"9","author":"Guilhot","year":"2004","journal-title":"The Oncologist"},{"key":"10.1157\/13111687_bib3","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood-2004-01-0246","article-title":"Imatinib targets other than bcr\/abl and their clinical relevance in myeloid disorders","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"key":"10.1157\/13111687_bib4","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM200104053441404","article-title":"Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumour","volume":"344","author":"Joensuu","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1157\/13111687_bib5","first-page":"3034","article-title":"Imatinib mesylate in the treatment of metastatic and\/or unresecable malignant gastrointestinal stromal tumours","volume":"8","author":"Dagher","year":"2002","journal-title":"Clin Can Res"},{"key":"10.1157\/13111687_bib6","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1157\/13111687_bib7","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/annonc\/mdi317","article-title":"Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series","volume":"16","author":"Dreseman","year":"2007","journal-title":"Ann Oncol"},{"issue":"Suppl 6","key":"10.1157\/13111687_bib8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.seminoncol.2004.03.038","article-title":"Molecularly targeted treatment for dermatofibrosarcoma protuberans","volume":"2","author":"McArthur","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1157\/13111687_bib9","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable haematologic and cytogenic responses in patient with accelerated phase chronic myeloid leukaemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1157\/13111687_bib10","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronic-phase myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N. Engl J. Med"},{"key":"10.1157\/13111687_bib11","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/sj.leu.2402702","article-title":"Imatinib mesylate-induced hepatotoxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis","volume":"16","author":"Ohyashiki","year":"2002","journal-title":"Leukemia"},{"key":"10.1157\/13111687_bib12","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/sj.leu.2402910","article-title":"Histological features of acute hepatitis after imatinib mesylate treatment","volume":"17","author":"James","year":"2003","journal-title":"Leukemia"},{"key":"10.1157\/13111687_bib13","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1080\/10428190412331272721","article-title":"Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes","volume":"45","author":"Kikuchi","year":"2004","journal-title":"Leukemia Lymphoma"},{"key":"10.1157\/13111687_bib14","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0399-8320(04)95160-3","article-title":"Imatinib mesylate-induced acute cytolytic hepatitis","author":"Rocca","year":"2004","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1157\/13111687_bib15","first-page":"75","article-title":"Imatinib (gleevec)-induced hepatotoxicity","volume":"39","author":"Ayuob","year":"2005","journal-title":"J Clin Gastroeneterol"},{"key":"10.1157\/13111687_bib16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1532\/IJH97.05034","article-title":"Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its managements","volume":"82","author":"Ikuta","year":"2005","journal-title":"Int J Hematol"},{"key":"10.1157\/13111687_bib17","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/10428190600593877","article-title":"Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukaemia in the chronic phase","volume":"47","author":"Yamazaki","year":"2006","journal-title":"Leukemia Lymphoma"},{"key":"10.1157\/13111687_bib18","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/01.meg.0000243867.56454.13","article-title":"Imatinib mesylate-induced acute hepatitis with autoimmune features","volume":"18","author":"Dhalluin-Venier","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1157\/13111687_bib19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ajh.20486","article-title":"Imatinib mesylate as a cause of acute liver failure","volume":"81","author":"Cross","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1157\/13111687_bib20","first-page":"357","article-title":"Corticosteroids can reverse severe imatinibinduced hepatotoxity","volume":"91","author":"Ferrero","year":"2006","journal-title":"J Hematol"},{"key":"10.1157\/13111687_bib21","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s10620-006-9117-1","article-title":"Imatinib mesylate (gleevec) hepatotoxicity","volume":"52","author":"Mindikoglu","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1157\/13111687_bib22","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2003-07-2323","article-title":"Fatal hepatic necrosis following imatinib mesylate therapy","volume":"102","author":"Lin","year":"2003","journal-title":"Blood"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570507724068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570507724068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T20:59:51Z","timestamp":1545512391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570507724068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0210570507724068"],"URL":"https:\/\/doi.org\/10.1157\/13111687","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}